RTTNews BiotechDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 22:19:02(美东 10:19)·⟳ 抓取 22:19:18 +16s·⚡ 决策 10-21 22:20:55 +1m37s·5.7 天前
康方生物合作伙伴Summit就依沃西胆道癌II/III期试验EA2251与ECOG-ACRIN合作——同一公告的再次转述，无新增事实
search_processed_events命中同一具体催化：今日10:17 UTC已处理Summit官方IR首发（9926.HK/SMMT.US，不做），12:51 UTC又处理Investing.com改写稿（不做）。本条14:19 UTC的RTTNews仅为第三轮媒体转述，EA2251试验设计、第七项国际注册试验、HARMONi-GI1阳性OS、10月25日ESMO公布、Q4美国中心激活等事实全部已在既有记录中，无新增金额、指引、数据或监管事实，按查重纪律直接AVOID，不再重复Web/行情/先例研究。
📄 原文RTTNews Biotech↗ 原文
Akeso's Ivonescimab To Be Evaluated In Global Phase II/III Biliary Tract Cancer Trial
Akeso, Inc. (9926.HK) announced that its partner Summit Therapeutics (SMMT) has entered into a clinical trial collabora…
不做 康方生物（09926.HK）
同一EA2251胆道癌II/III期合作公告今日已两次研判，本条RTTNews为无新增事实的媒体转述；且港股已收盘，无可执行窗口；学术协作组试验无金额/规模/读出，10月25日ESMO数据才是独立催化，届时另行评估
不做 Summit Therapeutics（SMMT.US）
同一公告10:17 UTC已研判不做，本条无增量；早期协作组供药型试验相对其大市值的短期期权价值有限，盘中反应极微、量薄，无正期望edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
RTTNews此稿是今日稍早Summit与ECOG-ACRIN胆道癌II/III期合作公告的又一转述，无新增事实；该学术协作组试验无金额、无入组规模、无读出时点，距数据与收入数年，事件本身在前两轮研判中即缺乏可交易edge，维持不做。
🔎 新鲜度:最早出现 2026-10-21 · 扩散 high · price-in 风险 medium ↗
主要风险
- 10月25日ESMO主席研讨会公布HARMONi-GI1详细OS数据才是该瘤种真正的近期催化，届时若数据超预期可能独立驱动重估，应作为新事件另行研判
- 本条对EA2251的入组规模、启动进度与数据时点均无披露，远期试验进展存在不及预期风险
先例如何影响了这次决策
对本次决策的影响:查重早停直接决定AVOID；前两轮对同一公告的研判结论（软催化、无金额/规模/读出、无edge）构成本次不做的依据
方向:不适用：本条在跨源查重阶段即命中同一具体催化的已处理记录，按早停纪律不再重复历史先例研究
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 1,653 ms
{"result": "search_processed_events:agent query=`akeso ivonescimab biliary tract cancer ecog-acrin ea2251 phase ii/iii | summit therapeutics ivonescimab btc registrational trial collaboration | 康方生物 依沃西 胆道癌 harmoni-gi1 总生存期 esmo `；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、23321 条本臂决策(完整)，返回 6 条候选。\n• 10-2
原文全文
展开原文 · 2,543 字
Akeso, Inc. (9926.HK) announced that its partner Summit Therapeutics (SMMT) has entered into a clinical trial collaboration with ECOG-ACRIN Cancer Research Group to evaluate Ivonescimab in a registration-enabling Phase II/III study in biliary tract cancer.
Biliary tract cancer (BTC) is a group of rare and aggressive cancers that affect the bile ducts and gallbladder. Because the disease is often diagnosed at an advanced stage, treatment options remain limited and survival rates are generally poor.
The new study, known as EA2251, will evaluate Ivonescimab in combination with chemotherapy against current immunotherapy-based treatment regimens that include Merk's pembrolizumab or durvalumab plus chemotherapy in previously untreated patients with advanced biliary tract cancer.
According to the company, this is the seventh international registrational Phase II/III trial for Ivonescimab and the second Phase III registrational study evaluating the drug in biliary tract cancer.
The collaboration follows positive results from the Akeso's Phase III HARMONi-GI1 study in China, which evaluated Ivonescimab plus chemotherapy against durvalumab plus chemotherapy in first-line biliary tract cancer. The company reported that the study achieved a statistically significant and clinically meaningful improvement in overall survival.
Clinical trial site activations in the United States are expected to begin in the fourth quarter of 2026.
Ivonescimab is a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and immune evasion. The therapy is being studied across multiple cancer types as part of a broad global clinical development program.
Detailed results from the Phase III HARMONi-GI1 study are scheduled to be presented at the European Society for Medical Oncology 2026 Congress on October 25, 2026.
Akeso has licensed the rights to develop and commercialize Ivonescimab in the United States, Canada, Europe, Japan and several other international markets to Summit Therapeutics under a partnership agreement.
9926.HK closed Wednesday's trading at $92.80, up 1.53%.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
Biliary tract cancer (BTC) is a group of rare and aggressive cancers that affect the bile ducts and gallbladder. Because the disease is often diagnosed at an advanced stage, treatment options remain limited and survival rates are generally poor.
The new study, known as EA2251, will evaluate Ivonescimab in combination with chemotherapy against current immunotherapy-based treatment regimens that include Merk's pembrolizumab or durvalumab plus chemotherapy in previously untreated patients with advanced biliary tract cancer.
According to the company, this is the seventh international registrational Phase II/III trial for Ivonescimab and the second Phase III registrational study evaluating the drug in biliary tract cancer.
The collaboration follows positive results from the Akeso's Phase III HARMONi-GI1 study in China, which evaluated Ivonescimab plus chemotherapy against durvalumab plus chemotherapy in first-line biliary tract cancer. The company reported that the study achieved a statistically significant and clinically meaningful improvement in overall survival.
Clinical trial site activations in the United States are expected to begin in the fourth quarter of 2026.
Ivonescimab is a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and immune evasion. The therapy is being studied across multiple cancer types as part of a broad global clinical development program.
Detailed results from the Phase III HARMONi-GI1 study are scheduled to be presented at the European Society for Medical Oncology 2026 Congress on October 25, 2026.
Akeso has licensed the rights to develop and commercialize Ivonescimab in the United States, Canada, Europe, Japan and several other international markets to Summit Therapeutics under a partnership agreement.
9926.HK closed Wednesday's trading at $92.80, up 1.53%.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
0bb1e2af26· 2026-10-21 22:20 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前